Open AccessMitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma
Author(s) -
Felix Megerle,
W.M. Herrmann,
Wiebke Schloetelburg,
Cristina L. Ronchi,
Alina Pulzer,
Marcus Quinkler,
Felix Beuschlein,
Stefanie Hahner,
Matthias Kroiß,
Martin Faßnacht
Publication year - 2018
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2017-02591
Subject(s) - mitotane , medicine , adrenocortical carcinoma , hazard ratio , proportional hazards model , oncology , cohort , interquartile range , urology , gastroenterology , confidence interval
Although mitotane is the only approved drug for the treatment of adrenocortical carcinoma (ACC), data on monotherapy in advanced disease are still scarce.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom